Morning all,
Not to cross promote, but DXB is also presenting at the Bioshares Biotech Summit today and they have released an event-specific preso that includes some interesting info about global partnering trends and the mechanics of licensing deals in the healthcare/life sciences space, which I found relevant to NEU so I thought I’d share.g
Link to full presentation available here:
https://investors.dimerix.com/DownloadFile.axd?file=/Report/ComNews/20240712/02827240.pdf
Also, it’s 2 years to the day since the NNZ-2591 Phase 2 trial in Angelman Syndrome commenced. We must be getting close to a result. Link to that announcement:
https://www.neurenpharma.com/pdf/d9b6c1d7-c009-441c-bf1a-538251f82f7d/Neuren-commences-Phase-2-trial-of-NNZ2591-in-Angelman.pdf
Neuren Media and Analyst Coverage, page-1239
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.52 |
Change
0.660(3.32%) |
Mkt cap ! $2.622B | |||
| Open | High | Low | Value | Volume |
| $20.00 | $20.66 | $19.94 | $6.431M | 315.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1024 | $20.52 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.53 | 285 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |